“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?

Expert Name
Prof. Kaharu Sumino

Several recent studies assessed the benefit of as-needed inhaled corticosteroid (ICS) treatment for mild asthma. An advantage of this approach is the ICS sparing effect, which was evident both in randomised clinical trials and practice studies. The traditional management of persistent asthma consists of a controller medication daily and reliever medication as needed. “This procedure was the guideline´s first choice…

Vaping identified as risk factor for asthma

Expert Name
Prof. Theresa To

An analysis of Canadian survey data found an association between e-cigarette smoking and asthma. Not only did vaping increase the odds for asthma by 19%; those who had asthma were also more prone to exacerbation. Every 2 years, the Canadian Community Health Survey gathers health-related data of Canadian inhabitants at the regional level. The 2019 survey in Ontario reported 23%…

Obesity: A risk factor for new-onset asthma and worse asthma control

Expert Name
Prof. Fernando Holguin

For at least 2 decades, it has been widely recognised that obesity increases asthma incidence, impairs asthma control, diminishes response to therapy with inhaled corticosteroids (ICS), and increases the chances of an asthma exacerbation. Abdominal obesity appears the most important risk factor. Obesity stimulates bronchial hyperresponsiveness and leads to a steeper loss of lung function. “While there are varying degrees…

Does COPD plus COVID-19 equal higher mortality?

Expert Name
Dr Jacob Schwartz

The evaluation of chronic obstructive pulmonary disease (COPD) patients with COVID-19 did not find increased mortality, nor a negative impact of exacerbation status. Similar results were found for asthma and COVID-19. “We sought to assess whether COPD or asthma are risk factors for intubation in COVID-19, as well as mortality in COVID-19,” Dr Jacob Schwartz (Lenox Hill Hospital, NY, USA)…

Tezepelumab – good success rates in various types of severe asthma

Expert Name
Prof. Michael E. Wechsler

Tezepelumab showed convincing results for the treatment of severe asthma. Besides significantly reducing exacerbation rates in many different inflammatory profiles, the first-in-class TSLP blocker also improved asthma control and quality of life. Tezepelumab is a monoclonal antibody with specific inhibition of thymic stromal lymphopoietin (TSLP) resulting in hindering TSLP to cooperate with its receptor thus acting upstream of various cytokines…

Benralizumab lives up to its phase 3 results in real-world findings

Expert Name
Dr Donna Carstens

The efficacy of benralizumab for severe eosinophilic asthma was confirmed in a retrospective cohort trial utilising US claims data. Exacerbation rates and the use of controller medication were significantly diminished with benralizumab treatment. After demonstrating significant results in phase 3 trials, the anti-IL-5 antibody benralizumab has been approved by the EMA as add-on maintenance medication in adult patients with severe…

IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma

Expert Name
Prof. Leonhard B. Bacharier

Dupilumab reduced annualised exacerbations in schoolchildren with uncontrolled moderate-to-severe asthma by >50% compared with placebo. The safety profile was similar to that seen in adolescents and adults. These were the results of the VOYAGE trial. Despite optimised standard-of-care therapy, children with moderate-to-severe asthma may continue to have uncontrolled disease. The IL-4/13 blocker dupilumab has previously been shown to be effective…

Long-term efficacy data of dupilumab for eosinophilic oesophagitis

Expert Name
Dr Evan S. Dellon

Dupilumab showed maintained patient benefits in an eosinophilic oesophagitis (EoE) population. The 28-week extended treatment period of the randomised, double-blind, placebo-controlled, phase 3 LIBERTY EoE TREET trial showed sustained symptomatic, histologic, and endoscopic benefits of dupilumab. The drug was well tolerated and few severe adverse events were reported. Dupilumab is a human monoclonal antibody inhibiting IL-4 and IL-13 signalling. Part…

Abrocitinib flexibly dosed for moderate-to-severe atopic dermatitis

Expert Name
Dr Andrew Blauvelt

Patients with atopic dermatitis (AD) suffer from chronic inflammation of the skin. It is a common and unpredictable skin disease, making it important to find an effective and safe treatment. Abrocitinib is a promising molecule for the potential treatment of AD. If approved, it could prevent inconvenient flares in patients. AD is associated with uncertainty in daily life. The unpredictability…

The efficacy and safety of crisaborole in paediatric patients with allergic dermatitis

Expert Name
Dr. Peter Lio

Crisaborole is indicated for the topical treatment of mild-to-moderate atopic dermatitis. It is effective and safe in treating patients aged ≥2 years with allergic dermatitis irrespective of atopic comorbidities. Crisaborole ointment 2% is an anti-inflammatory inhibitor of phosphodiesterase 4. It is available in the USA for topical treatment targeting paediatric patients with mild-to-moderate allergic dermatitis (AD) who are at an…